Sanofi commitments offered in EU probe of flu vaccine
( July 8, 2026, 09:46 GMT | Official Statement) -- MLex Summary: Sanofi has offered to make changes over how it communicates about a rival flu vaccine, as part of commitments designed to address a European Commission antitrust case. The EU concerns focus on suggestions that the evidentiary basis for the rival Fluad treatment is weaker than that for Sanofi's own Efluelda. The company will make statements on its website and in promotional materials to address those previous comments, which the commission suspected may have been anticompetitive. The regulator is now seeking market feedback on the draft package. The statement is attached. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.